马尔可夫模型预测南非私营与公共诊所抗逆转录病毒治疗成本和结果

数据集获取（Figshare）

• 源站标题：A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa
• DOI：10.1371/journal.pone.0053570
• 发布日期：2013-02-06
• 文件数：7 个
• 文件总体积：10.33 MB
• 源站页面：https://plos.figshare.com/articles/dataset/A_Novel_Markov_Model_Projecting_Costs_and_Outcomes_of_Providing_Antiretroviral_Therapy_to_Public_Patients_in_Private_Practices_versus_Public_Clinics_in_South_Africa__/155898

命令行下载

curl -L -o "Figure_S1.tif" "https://ndownloader.figshare.com/files/482668"
curl -L -o "Figure_S2.tif" "https://ndownloader.figshare.com/files/482670"
curl -L -o "Figure_S3.tif" "https://ndownloader.figshare.com/files/482673"
curl -L -o "Table_S1.xls" "https://ndownloader.figshare.com/files/482674"
curl -L -o "Table_S2.xls" "https://ndownloader.figshare.com/files/482676"
curl -L -o "Table_S3.tif" "https://ndownloader.figshare.com/files/482677"
curl -L -o "Table_S4.xls" "https://ndownloader.figshare.com/files/482679"

文件清单

• Figure_S1.tif（3.70 MB）
• Figure_S2.tif（3.87 MB）
• Figure_S3.tif（563.76 KB）
• Table_S1.xls（98.82 KB）
• Table_S2.xls（86.02 KB）
• Table_S3.tif（1.88 MB）
• Table_S4.xls（135.68 KB）

文件总体积 10.33 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Introduction
Providing private antiretroviral therapy (ART) care for public sector patients could increase access to ART in low- and middle-income countries. We compared the costs and outcomes of a private-care and a public-care ART program in South Africa.
Methods
A novel Markov model was developed from the public-care program. Patients were first tunneled for 6 months in their baseline CD4 category before being distributed into a dynamic CD4 and viral load model. Patients were allowed to return to ART care from loss to follow up (LTFU). We then populated this modeling framework with estimates derived from the private-care program to externally validate the model.
Results
Baseline characteristics were similar in the two programs. Clinic visit utilization was higher and death rates were lower in the first few years on ART in the public-care program. After 10 years on ART we estimated the following outcomes in the public-care and private-care programs respectively: viral load 500 cells/μl 33% and 37%, LTFU 14% and 14%, and death 27% and 32%. Lifetime undiscounted survival estimates were 14.1 (95%CI 13.2–14.9) and (95%CI 12.7–14.5) years with costs of 18,734 (95%CI 12,588–14,022) and 13,062 (95%CI 12,077–14,047) USD in the private-care and public-care programs respectively. When clinic visit utilization in the public-care program was reduced by two thirds after the initial 6 months on ART, which is similar to their current practice, the costs were comparable between the programs.
Conclusions
Using a novel Markov model, we determined that the private-care program had similar outcomes but lower costs than the public-care program, largely due to lower visit frequencies. These findings have important implications for increasing and sustaining coverage of patients in need of ART care in resource-limited settings.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0053570（source: https://plos.figshare.com/articles/dataset/A_Novel_Markov_Model_Projecting_Costs_and_Outcomes_of_Providing_Antiretroviral_Therapy_to_Public_Patients_in_Private_Practices_versus_Public_Clinics_in_South_Africa__/155898）。